AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales
Tue 30 Sep 25, 07:05 PMPresenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
Wed 19 Feb 25, 11:00 AMPresenting on the Emerging Growth Conference 75 Day 2 on September 26
Wed 25 Sep 24, 11:00 AM18 Stocks Moving in Friday's Pre-Market Session
Fri 08 Oct 21, 11:34 AM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -3.78651M | -2.85425M | -8.38447M | -2.92721M | -4.63274M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | -3.78651M | -2.59110M | -8.39823M | -2.90478M | -4.64476M |
| Selling general administrative | 4.15M | 3.47M | 6.08M | 3.17M | 4.96M |
| Selling and marketing expenses | 0.93M | 0.42M | 0.29M | 0.87M | 0.86M |
| Gross profit | 1.31M | 0.52M | 0.09M | 1.83M | 1.72M |
| Reconciled depreciation | 0.05M | 0.04M | 0.04M | 0.04M | 0.00529M |
| Ebit | -3.61454M | -3.11741M | -7.19374M | -2.91691M | -4.62077M |
| Ebitda | -3.56588M | -3.05302M | -7.14088M | -2.87285M | -4.61544M |
| Depreciation and amortization | 0.05M | 0.06M | 0.05M | 0.04M | 0.00533M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | -3.56884M | -3.11741M | -7.19374M | -2.91691M | -4.62077M |
| Other operating expenses | 5.21M | 3.88M | 7.34M | 5.44M | 7.01M |
| Interest expense | 0.00965M | 0.00618M | 0.01M | 0.02M | 0.00004M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.12M | 0.02M | 0.00920M | 0.00000M | 0.00004M |
| Net interest income | 0.11M | 0.02M | -0.00456M | -0.02163M | 0.00004M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | -0.31469M | -0.26316M | 0.01M | -0.02243M | 0.01M |
| Total revenue | 1.80M | 0.77M | 0.15M | 2.52M | 2.39M |
| Total operating expenses | 4.72M | 3.64M | 7.29M | 4.75M | 6.34M |
| Cost of revenue | 0.50M | 0.24M | 0.05M | 0.69M | 0.67M |
| Total other income expense net | -0.48666M | 0.26M | -1.19072M | -0.01030M | -0.01198M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | -3.78651M | -2.85425M | -8.38447M | -2.92721M | -4.63274M |
| Net income applicable to common shares | -3.78651M | -2.85425M | -8.38447M | -2.92721M | -4.65642M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 21.99M | 24.86M | 27.05M | 6.20M | 8.56M |
| Intangible assets | - | - | - | - | 0.00000M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.16M | 0.57M | 0.08M | 0.03M | 0.05M |
| Total liab | 2.37M | 1.68M | 1.16M | 0.56M | 1.21M |
| Total stockholder equity | 19.62M | 23.18M | 25.90M | 5.64M | 7.35M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 0.04M | 0.75M | 0.02M | 0.04M | 0.48M |
| Common stock | 88.44M | 88.44M | 88.36M | 62.43M | 60.51M |
| Capital stock | 88.44M | 88.44M | 88.36M | 62.43M | 60.51M |
| Retained earnings | -72.05540M | -68.42528M | -65.93289M | -57.91642M | -56.86052M |
| Other liab | 0.00188M | 0.00004M | 0.04M | 0.02M | 0.01M |
| Good will | - | - | - | - | 0.00000M |
| Other assets | 1.22M | 0.96M | 1.27M | 1.72M | 1.86M |
| Cash | 17.16M | 22.11M | 25.05M | 3.25M | 5.12M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2.22M | 1.50M | 1.12M | 0.52M | 1.20M |
| Current deferred revenue | 0.70M | - | 0.97M | 0.27M | - |
| Net debt | -16.97067M | -21.90049M | -25.02678M | -3.18936M | -5.11989M |
| Short term debt | 0.29M | 0.03M | 0.02M | 0.04M | 0.00000M |
| Short long term debt | - | - | - | - | 0.00000M |
| Short long term debt total | 0.19M | 0.21M | 0.02M | 0.06M | 0.00000M |
| Other stockholder equity | 3.24M | 23.18M | 25.90M | 5.64M | 7.35M |
| Property plant equipment | 0.20M | 0.23M | 0.03M | 0.07M | 0.02M |
| Total current assets | 20.41M | 23.67M | 25.75M | 4.41M | 6.68M |
| Long term investments | 0.16M | - | - | - | 0.00000M |
| Net tangible assets | 19.62M | 23.18M | 25.90M | 5.64M | 7.35M |
| Short term investments | 1.83M | - | - | - | 0.00000M |
| Net receivables | 0.42M | 0.66M | 0.33M | 0.33M | 0.97M |
| Long term debt | - | - | - | - | 0.00000M |
| Inventory | 0.84M | 0.33M | 0.29M | 0.80M | 0.54M |
| Accounts payable | 1.19M | 0.72M | 0.11M | 0.16M | 0.72M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | 3.24M | 3.17M | 3.47M | 1.13M | 3.70M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 1.22M | 0.96M | 1.27M | 1.72M | 1.86M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 1.58M | 1.18M | 1.30M | 1.79M | 1.88M |
| Capital lease obligations | 0.19M | 0.21M | 0.02M | 0.06M | 0.00000M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -2.62128M | 0.01M | 0.00257M | -0.00086M | -0.00201M |
| Change to liabilities | 0.69M | 0.29M | 0.59M | -0.36244M | 0.43M |
| Total cashflows from investing activities | -2.62128M | 0.01M | 0.00257M | -0.00086M | -0.00201M |
| Net borrowings | -0.03501M | -0.03626M | -0.04061M | -0.40804M | -0.40804M |
| Total cash from financing activities | -0.04467M | -0.04245M | 26.48M | 1.16M | 2.07M |
| Change to operating activities | 1.26M | -0.49414M | -0.04507M | 0.02M | 0.09M |
| Net income | -3.78651M | -2.59110M | -8.38447M | -2.92721M | -4.63274M |
| Change in cash | -4.95051M | -2.93700M | 21.80M | -1.86942M | 0.39M |
| Begin period cash flow | 22.11M | 25.05M | 3.25M | 5.12M | 4.73M |
| End period cash flow | 17.16M | 22.11M | 25.05M | 3.25M | 5.12M |
| Total cash from operating activities | -2.59519M | -2.54849M | -4.07875M | -3.14733M | -1.79858M |
| Issuance of capital stock | 0.00000M | 0.00000M | 29.28M | 1.96M | 2.89M |
| Depreciation | 0.05M | 0.04M | 0.04M | 0.04M | 0.00529M |
| Other cashflows from investing activities | 0.12M | 0.02M | 0.00920M | 0.00920M | 0.00004M |
| Dividends paid | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Change to inventory | -0.77610M | 0.28M | 0.96M | -0.11363M | 0.26M |
| Change to account receivables | 0.23M | -0.33700M | 0.02M | 0.64M | 0.68M |
| Sale purchase of stock | - | - | - | - | 2.89M |
| Other cashflows from financing activities | -0.00965M | -0.00618M | -2.54784M | -0.39217M | -0.82505M |
| Change to netincome | -0.25625M | -0.05023M | 2.74M | -0.44544M | 1.39M |
| Capital expenditures | 0.00774M | 0.01M | 0.00663M | 0.00086M | 0.00205M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | 1.40M | -0.26992M | 1.53M | 0.18M | 1.44M |
| Stock based compensation | 0.23M | 0.09M | 2.12M | -0.53391M | 1.34M |
| Other non cash items | 0.47M | 2.55M | 1.25M | -0.53993M | 0.10M |
| Free cash flow | -2.60293M | -2.55854M | -4.08538M | -3.14819M | -1.80063M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IMRN Immuron Ltd ADR |
0.03 3.84% | 0.87 | - | - | 4.37 | 1.32 | 0.94 | -0.8638 |
| NVO Novo Nordisk A/S |
-1.06 2.66% | 38.72 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 38.88 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
38.30 8.31% | 499.17 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-9.57 1.22% | 772.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
62 Lygon Street, Carlton, VIC, Australia, 3053
| Name | Title | Year Born |
|---|---|---|
| Dr. Jerry Kanellos Ph.D. | Chief Operating Officer | 1961 |
| Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA | Chief Exec. Officer | 1968 |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | CFO & Company Sec. | 1959 |
| Mr. David Lyon | Head of Marketing | NA |
| Dr. Dan Ruben Peres | Chief Medical Officer | 1976 |
| Mr. Flavio Palumbo | Chief Commercial Officer | NA |
| Mr. Steven George Lydeamore CPA, M.B.A. | Chief Executive Officer | 1968 |
| Mr. Flavio Palumbo | Chief Commercial Officer | 1974 |
| Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. | CFO & Company Secretary | 1959 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...